Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer

Two Years of Adjuvant Tamoxifen Provides a Survival Benefit Compared With No Systemic Treatment in Premenopausal Patients With Primary Breast Cancer: Long-Term Follow-Up (> 25 years) of the Phase III SBII:2pre Trial

(2016) Maria Ekholm et al.   JOURNAL OF CLINICAL ONCOLOGY

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

(2013) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit

(2012) Josefine Bostner et al.   BREAST CANCER RESEARCH AND TREATMENT

Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen

(2010) Mahmoud R. Khoshnoud et al.   BREAST CANCER RESEARCH AND TREATMENT

Ratio of 17HSD1 to 17HSD2 Protein Expression Predicts the Outcome of Tamoxifen Treatment in Postmenopausal Breast Cancer Patients

(2009) A. Jansson et al.   CLINICAL CANCER RESEARCH